Symbols

HALO

Halozyme Therapeutics·NASDAQ

--(--)

HALO fundamentals

HALO Q4 2025 Earnings

Halozyme Therapeutics (HALO) released its earnings on Feb 17, 2026: revenue was 451.77M (YoY +51.60%), beat estimates; EPS was -0.24 (YoY -119.05%), missed estimates.

Revenue / YoY

451.77M

+51.60%

EPS / YoY

-0.24

-119.05%

Report date

Feb 17, 2026

HALO Earnings Call Summary for Q4,2025

Record Revenue Growth: 2025 total revenue $1.4B (+38%), royalty $868M (+52%). 2026 guidance: $1.71-1.81B revenue, $1.13-1.17B royalty.
Blockbuster Momentum: DARZALEX SC sales $14.4B, VYVGART Hytrulo $4.15B. 2028 projections: DARZALEX $18B, PHESGO $3.6B.
Strategic Expansion: 2025 acquisitions add Hypercon tech; 2026 pipeline expands to 15 products with 6 new Phase I starts.
Innovative Opportunities: ENHANZE ADC data shows 75% lower Cmax vs IV; 2026 Phase I starts for Hypercon in approved drugs.
Financial Strength: 2025 non-GAAP EPS $4.15, 2026 target $7.75-8.25. Debt/EBITDA <1x by end-2026.

Earnings

EPS

Revenue

Revenue & Expenses

HALO has released its 2025 Q4 earnings report, with revenue of 451.77M, reflecting a YoY change of 51.60%, and net profit of -141.59M, showing a YoY change of -203.34%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.

Key Indicators

Halozyme Therapeutics (HALO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Halozyme Therapeutics (HALO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Halozyme Therapeutics (HALO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Halozyme Therapeutics (HALO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown